TABLE 3.
Incidence and severity of macroscopic and microscopic lung lesions and presence of PRRSV and PCV2 nucleic acids and antigens in lungsa
| Group | Result for indicated lung lesionb:
|
Detected presence of:
|
||||
|---|---|---|---|---|---|---|
| PRRSV
|
PCV2
|
|||||
| Macroscopic | Microscopic | BAL fluid PCR | IHC | BAL fluid PCR | IHC | |
| Control | 1/10 (0.3 ± 0.3)A | 10/10 (1.2 ± 0.1)A | 0/10 | NAc | NA | NA |
| NV-PRRSV | 9/9 (50.1 ± 3.1)B | 9/9 (4.6 ± 0.4)B | 9/9 | 8/9 | NA | NA |
| V-PRRSVd | 10/10 (13.2 ± 2.6)C | 10/10 (2.5 ± 0.3)AC | 10/10 | 0/10 | NA | NA |
| PCV2-V-PRRSVd | 10/10 (31.7 ± 5.0)D | 10/10 (3.3 ± 0.5)BC | 10/10 | 4/10 | 10/10 | 0/10 |
| PCV2 | 4/10 (1.0 ± 0.6)A | 10/10 (1.2 ± 0.1)A | 0/10 | NA | 10/10 | 0/10 |
| PCV2-Vd | 3/10 (2.2 ± 1.3)AC | 10/10 (1.8 ± 0.2)A | 8/10 | 0/10 | 10/10 | 0/10 |
| Vd | 0/10 (0.0 ± 0.0)A | 8/10 (1.2 ± 0.3)A | 2/10 | 0/10 | NA | NA |
a
Detected by PCR on BAL fluid and IHC at 14 days after PRRSV challenge.
b
Data presented as incidences/total and group means ± standard errors (for macroscopic lesions, mean of the percentage of lung grossly affected by lesions ranging from 0 to 100%; for microscopic lesions, mean of the interstitial pneumonia score ranging from 0 [normal] to 6 [severe, diffuse]). Values within a column with no common superscript represent significantly (P < 0.05) different group means.
c
NA, not applicable.
d
Vaccinated with Ingelvac PRRS ATP MLV vaccine (Boehringer Ingelheim Vetmedica, Inc., St. Joseph, MO).